$1.26
-0.05-3.82%
Last update: Nov 12, 4:15 AM
ProQR Therapeutics NV (PRQR) Stock Price, Quote, News & History
PRQRNASDAQ
ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.
You can purchase shares of ProQR Therapeutics (NASDAQ:PRQR) through any online brokerage.
Other companies in ProQR Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
ProQR Therapeutics has a consensus price target of $8.00.
The stock price for ProQR Therapeutics (NASDAQ: PRQR) is $1.26 last updated November 12, 2026 at 4:15 AM EST.
There are no upcoming dividends for ProQR Therapeutics.
ProQR Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for ProQR Therapeutics.
ProQR Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The...
